Emergent BioSolutions Inc. (EBS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Emergent BioSolutions Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Emergent BioSolutions Inc. (EBS) has returned -32.85% so far this year and 70.78% over the past 12 months. Over the last ten years, EBS has returned -13.28% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Nov 15, 2006, EBS's average daily return is +0.08%, while the average monthly return is +1.69%. At this rate, your investment would double in approximately 3.4 years.

Historically, 53% of months were positive and 47% were negative. The best month was May 2024 with a return of +203.2%, while the worst month was Nov 2007 at -44.5%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 9 months.

On a daily basis, EBS closed higher 49% of trading days. The best single day was Feb 21, 2024 with a return of +78.3%, while the worst single day was Aug 7, 2024 at -42.0%.

Emergent BioSolutions Inc. has an annualized alpha of 10.16%, beta of 1.04, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since November 16, 2006.

• This stock participated in 141.59% of S&P 500 Index downside but only 104.87% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EBS ranks 73 for risk / return — better than 73% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Emergent BioSolutions Inc. (EBS) and compare them to a chosen benchmark (S&P 500 Index).

Emergent BioSolutions Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Emergent BioSolutions Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Emergent BioSolutions Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Emergent BioSolutions Inc. was 98.89%, occurring on Feb 7, 2024. The portfolio has not yet recovered.

The current Emergent BioSolutions Inc. drawdown is 93.85%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Emergent BioSolutions Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Emergent BioSolutions Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.